39O1 Stock Chart & Stats
€0.84
>-€0.01(-0.59%)
At close: 4:00 PM EDT
€0.84
>-€0.01(-0.59%)
Day’s Range― - ―
52-Week Range€0.77 - €2.26
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€10.53M
Enterprise Value€14.71
Total Cash (Recent Filing)€13.37M
Total Debt (Recent Filing)€29.12M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Jan 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.40
Shares Outstanding12,144,586
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-2.76
Price to Sales (P/S)0.71
P/FCF Ratio-1.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Deep Breeding PipelineA very large and expanding breeding pipeline creates a durable product-development cadence, increasing the probability of steady new variety introductions and licensing opportunities. This breadth of germplasm and AI-enabled discovery supports long-term competitive differentiation and product flow into commercial seasons.
Biotech & Commercial ReadinessEstablished biotech credentials and concrete commercialization enablers materially raise the company's ability to monetize advanced traits. Regulatory approvals and platform tools reduce technical barriers, enabling licensing, trait commercialization, and scale-up across seasons rather than relying solely on short-term product cycles.
Leadership And RestructuringRecent leadership continuity, returning CFO experience and CEO insider investment, combined with aggressive cost cuts and a rebuilt sales force, strengthen governance and execution capacity. These structural changes improve operating discipline and alignment necessary to convert R&D and pipeline assets into sustainable commercial revenue.
Bears Say
Stressed Balance SheetChronic negative equity and a recent jump in debt reduce financial flexibility and elevate refinancing and dilution risk. A fragile capital structure constrains the company's ability to fund multi-year breeding programs, scale production, or absorb regulatory-driven delays without dilutive financing or operational retrenchment.
Weak Cash GenerationSustained negative operating and free cash flow means the business cannot reliably self-fund R&D, seed multiplication, or commercial rollouts. Over time this forces dependence on external capital, which may be costly or dilutive and could compress the timeline for converting pipeline investments into lasting revenue streams.
Revenue Decline & Regulatory/execution RiskA sharp revenue drop amid strategic transition reduces near-term visibility and increases reliance on successful commercialization execution. Coupled with dependency on regulatory approvals for GMO products, this limits predictable monetization of the pipeline and raises downside risk if product launches or approvals are delayed.
39O1 FAQ
What was Origin Agritech Limited’s price range in the past 12 months?
Origin Agritech Limited lowest stock price was €0.77 and its highest was €2.26 in the past 12 months.
What is Origin Agritech Limited’s market cap?
Origin Agritech Limited’s market cap is €10.53M.
When is Origin Agritech Limited’s upcoming earnings report date?
Origin Agritech Limited’s upcoming earnings report date is Jan 11, 2027 which is in 163 days.
How were Origin Agritech Limited’s earnings last quarter?
Origin Agritech Limited released its earnings results on May 21, 2026. The company reported -€0.15 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.15.
Is Origin Agritech Limited overvalued?
According to Wall Street analysts Origin Agritech Limited’s price is currently Overvalued.
Does Origin Agritech Limited pay dividends?
Origin Agritech Limited does not currently pay dividends.
What is Origin Agritech Limited’s EPS estimate?
Origin Agritech Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Origin Agritech Limited have?
Origin Agritech Limited has 12,144,586 shares outstanding.
What happened to Origin Agritech Limited’s price movement after its last earnings report?
Origin Agritech Limited reported an EPS of -€0.15 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.047%.
Which hedge fund is a major shareholder of Origin Agritech Limited?
Currently, no hedge funds are holding shares in DE:39O1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Origin Agritech Limited
Established in 1997 and headquartered in Beijing, China, Origin Agritech Limited is a Chinese firm operating in two primary areas: agricultural biotechnology and an e-commerce platform. Its biotechnology segment focuses on the genetic enhancement and breeding of crop seeds, encompassing the development, production, and distribution of hybrid crop varieties and associated seed technologies. The firm also manages an e-commerce platform that caters to farmers across China, offering a diverse array of goods via online and mobile channels. This selection includes agricultural seeds like corn, rice, and vegetables, along with essential farming inputs such as fertilizers and agricultural chemicals. Additionally, the platform provides food, household items, and other consumer products. Origin Agritech maintains collaboration agreements with esteemed institutions such as the Chinese Academy of Agricultural Sciences, the National Maize Improvement Center, China Agricultural University, and Zhejiang University.
39O1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced view: clear operational and structural progress (large cuts in G&A, improved operating loss, strengthened biotech credentials, rebuilt sales force, sizable breeding pipeline and targeted variety acquisitions) alongside meaningful near-term challenges (a 31.9% revenue decline, ongoing net loss, modest cash position, higher inventories and dependency on regulatory timing for GMO commercialization). Management emphasized that the company is in the midpoint of a recovery plan and investing in sales and R&D to convert pipeline into revenue, but realization of that upside remains contingent on execution and policy developments.View all DE:39O1 earnings summariesTechnical Analysis
American Vanguard
―
Arcadia Biosciences
―
BioHarvest Sciences
―
Bioceres Crop Solutions
―
―









